Hematopoietic-cell transplantation for lymphoma in the era of genetically engineered cellular therapy: It's not quite time to scrap the old vehicle for the new car Review
| Authors: | Scordo, M.; Lin, R. J.; Sauter, C. S. |
| Review Title: | Hematopoietic-cell transplantation for lymphoma in the era of genetically engineered cellular therapy: It's not quite time to scrap the old vehicle for the new car |
| Abstract: | PURPOSE OF REVIEW: Second-line platinum-based salvage chemotherapy followed by high-dose chemotherapy and autologous hematopoietic-cell transplantation (AHCT) has remained the standard of care (SOC) for relapsed and primary refractory (r/r) diffuse large B-cell lymphoma (DLBCL) for greater than 2 decades. In the postrituximab era, this strategy has yielded disappointing outcomes for r/r patients with curability in less one-quarter of the patients by intention-to-treat. RECENT FINDINGS: Given the Food and Drug Administration (FDA) approval of chimeric antigen receptor (CAR) modified T cells directed against CD19 (CD19 CAR T) for DLBCL following two lines of therapy and/or failed AHCT, encouragement with this therapy in the second line for r/r patients has naturally prompted randomized phase III studies against the aforementioned SOC. The predominant hurdle to procession to AHCT is chemotherapy sensitivity after platinum-based salvage therapy. SUMMARY: In this review, we will discuss recent investigations to improve response rates in r/r DLBCL with the intent of proceeding to potentially curative AHCT, as well as investigations to decrease progression post-AHCT. In addition, data regarding currently FDA approved CD19 CAR T cells will be reviewed. Within 2-3 years, we will know if the multicenter/multinational studies of CD19 CAR T will replace SOC salvage therapy and AHCT in the second-line. The role of allogeneic HCT will also be briefly reviewed in the context of these therapies. |
| Journal Title: | Current Opinion in Hematology |
| Volume: | 26 |
| Issue: | 4 |
| ISSN: | 1065-6251 |
| Publisher: | Lippincott Williams & Wilkins, Ltd. |
| Date Published: | 2019-07-01 |
| Start Page: | 288 |
| End Page: | 293 |
| Language: | English |
| DOI: | 10.1097/moh.0000000000000515 |
| PUBMED: | 31170111 |
| PROVIDER: | scopus |
| PMCID: | PMC7428153 |
| DOI/URL: | |
| Notes: | Article -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work